Abstract
IntroductionIQOS is a heated tobacco product that was authorised as a modified risk tobacco product (MRTP) in July 2020. While it was removed from the US market in 2021 for legal reasons, as the first tobacco product to receive an ‘exposure modification’ MRTP order, surveillance of IQOS marketing is needed to inform regulation and policy for future MRTPs. The purpose of this study is to expand the current research on IQOS advertising in the USA by examining content and readership characteristics of IQOS ads in print magazines before and after US Food and Drug Administration MRTP authorisation.MethodsWe merged content analysis data with Kantar Media data on magazine placement and expenditures. Magazine readership data were obtained from MRI-Simmons. We compared data from pre-MRTP authorisation with data post-MRTP authorisation. This study was conducted in 2021.ResultsThere was one unique ad and there were 13 observations pre-MRTP, and eight unique ads and 132 observations post-MRTP. Compared with pre-MRTP ads, more post-MRTP ads featured Marlboro HeatSticks, including Amber HeatSticks, and featured people. All ads contained a warning label—most warning labels were cigarette specific. IQOS ads were featured in magazines that are especially popular among women.ConclusionsAfter receiving MRTP authorisation, IQOS increased ad expenditures in print magazines with a readership comprised of primarily women. If IQOS returns to the US market, it will be important for tobacco control to monitor their advertisement content, placement, and expenditures.
Funder
Center for Tobacco Products
Rutgers Cancer Institute of New Jersey
NIH Office of the Director
Subject
Public Health, Environmental and Occupational Health,Health (social science)
Reference17 articles.
1. Philip Morris International . IQOS heated tobacco products. n.d. Available: www.pmi.com/smoke-free-products/iqos-our-tobacco-heating-system
2. FDA authorizes marketing of IQOS tobacco heating system with ‘reduced exposure’ information. Press release. U.S. Food and Drug Administration; 2020.
3. Hammond H , Altria . PMI must stop IQOS sales in U.S. In: CSP Daily News [Internet]. 2021. Available: https://www.cspdailynews.com/tobacco/fda-issues-first-mrtp-reduced-nicotine-cigarettes
4. IQOS marketing in the US: the need to study the impact of FDA modified exposure authorization, marketing distribution channels, and potential targeting of consumers;Berg;Int J Environ Res Public Health,2021
5. Berg CJ , Romm KF , Bar-Zeev Y , et al . IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation. Tob Control 2021:tobaccocontrol-2021-056819. doi:10.1136/tobaccocontrol-2021-056819
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献